Clindamycin
clindamycin hydrochloride (oral) · clindamycin phosphate (injection, topical)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Serious skin & skin structure infections | Adults & pediatric | Monotherapy or combination | FDA Approved |
| Serious lower respiratory tract infections | Adults & pediatric | Monotherapy or combination | FDA Approved |
| Serious intra-abdominal infections | Adults & pediatric | Combination (with gram-negative cover) | FDA Approved |
| Septicemia | Adults & pediatric | Combination | FDA Approved |
| Bone & joint infections | Adults & pediatric | Monotherapy or combination | FDA Approved |
| Serious gynecological infections (e.g., PID, endometritis) | Adults | Combination (e.g., with gentamicin) | FDA Approved |
| Bacterial vaginosis (vaginal formulation) | Non-pregnant & pregnant women | Monotherapy | FDA Approved |
| Acne vulgaris (topical formulation) | Adults & adolescents ≥12 years | Monotherapy or combination | FDA Approved |
Clindamycin covers susceptible strains of staphylococci (including many MRSA isolates), streptococci, pneumococci, and most clinically important anaerobes. It is reserved for serious infections where less toxic agents are inappropriate, owing to its well-established association with Clostridioides difficile colitis. Its excellent bone and abscess penetration makes it particularly valuable for osteomyelitis and deep-seated soft tissue infections.
Streptococcal pharyngitis (penicillin-allergic patients): 7 mg/kg/dose TID for 10 days (max 300 mg/dose). Supported by IDSA guidelines. Evidence quality: High
Toxoplasmic encephalitis (HIV/AIDS): Clindamycin 600 mg IV/PO q6h combined with pyrimethamine and leucovorin. DHHS OI guidelines. Evidence quality: Moderate
Malaria (severe, adjunctive): Clindamycin 20 mg/kg/day in combination with quinine for 7 days. WHO guidelines. Evidence quality: Moderate
Aspiration pneumonia / lung abscess: Clindamycin IV 600 mg q8h, transitioned to oral when improving. IDSA guidelines list clindamycin as an alternative. Evidence quality: Moderate
MRSA skin & soft tissue infections (community-acquired): Clindamycin 300–450 mg PO TID. IDSA MRSA guidelines. Evidence quality: High
Group A streptococcal necrotizing fasciitis (toxin suppression): Clindamycin IV added to a beta-lactam to suppress toxin production. Evidence quality: Moderate
Endocarditis prophylaxis (penicillin-allergic): Single dose 600 mg PO 30–60 min before dental procedures in high-risk patients. AHA guidelines. Evidence quality: High
Clindamycin Dosing
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Skin & soft tissue infection — mild-moderate (oral) | 150 mg q6h | 300 mg q6h | 450 mg q6h | Reserve for penicillin-allergic patients or suspected MRSA Take with full glass of water |
| CA-MRSA skin abscess — oral step-down | 300 mg TID | 450 mg TID | 450 mg QID | Use after I&D when antibiotics are indicated IDSA MRSA guidelines 2011 |
| Serious anaerobic or gram-positive infection — IV | 600 mg q8h | 600–900 mg q8h | 2700 mg/day | Divide into 2–4 equal doses Max IV rate: 30 mg/min |
| Life-threatening infection (necrotizing fasciitis, sepsis) — IV | 900 mg q8h | 900 mg q8h | 4800 mg/day | Often combined with beta-lactam for toxin suppression in GAS Max single IM dose: 600 mg |
| Pelvic inflammatory disease — IV inpatient | 900 mg q8h | 900 mg q8h | 2700 mg/day | Combined with gentamicin; continue ≥48h after clinical improvement, then oral step-down (450 mg QID) CDC STI guidelines |
| Osteomyelitis — oral step-down | 300 mg q6h | 450 mg q6h | 450 mg q6h | Following IV induction; prolonged course (4–6 weeks total) Consider 600 mg TID if >75 kg |
| Endocarditis prophylaxis — dental procedures | 600 mg PO ×1 | — | 600 mg | Single dose 30–60 min before procedure; for penicillin-allergic patients only AHA 2021 guideline |
| Bacterial vaginosis — vaginal cream | One applicator (100 mg) intravaginally qHS | Same × 3–7 days | — | 7 days in pregnant patients; 3–7 days in non-pregnant patients Clindesse: single-dose option for non-pregnant |
| Acne vulgaris — topical | Apply 1% gel/lotion/foam to affected area daily or BID | Same | — | Usually combined with benzoyl peroxide to reduce resistance Cleocin T, Evoclin, Clindagel |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Serious infection — oral (≥10 kg) | 8 mg/kg/day in 3–4 divided doses | 8–16 mg/kg/day | 25 mg/kg/day | For weight ≤10 kg, minimum 37.5 mg TID regardless of weight |
| Severe infection — oral (≥10 kg) | 13 mg/kg/day in 3–4 divided doses | 16–20 mg/kg/day | 25 mg/kg/day | Use oral solution if unable to swallow capsules |
| Serious infection — IV/IM (1 month–16 years) | 20 mg/kg/day in 3–4 divided doses | 20–40 mg/kg/day | 40 mg/kg/day | Alternative: 350 mg/m2/day (serious) or 450 mg/m2/day (severe) |
| Neonates (≤1 month) — IV | 15 mg/kg/day in 3–4 divided doses | 15–20 mg/kg/day | 20 mg/kg/day | Lower dose may suffice for small premature infants 75 & 150 mg caps contain tartrazine (FD&C Yellow No. 5) |
| Strep pharyngitis — penicillin allergy (oral) | 7 mg/kg/dose TID | Same × 10 days | 300 mg/dose | IDSA guideline recommendation for PCN-allergic children |
Clindamycin must be diluted before IV infusion. Infuse over at least 10–60 minutes at a rate not exceeding 30 mg/min. Rapid IV push can cause cardiopulmonary arrest and hypotension. A single IM injection should not exceed 600 mg. When transitioning from IV to oral therapy, oral clindamycin can generally be started once clinical improvement is evident because the high oral bioavailability (~90%) permits reliable oral step-down.
Pharmacology
Mechanism of Action
Clindamycin is a semi-synthetic lincosamide antibiotic derived from lincomycin. It exerts its antimicrobial effect by binding reversibly to the 23S ribosomal RNA of the bacterial 50S ribosomal subunit, thereby inhibiting the translocation step of protein synthesis. This blocks peptide bond formation and halts the elongation of the growing peptide chain. Depending on organism susceptibility, drug concentration, and the inoculum size, clindamycin may be bacteriostatic or bactericidal. A clinically significant property is its capacity to suppress bacterial exotoxin production, which is particularly relevant in managing invasive group A streptococcal disease and staphylococcal toxic shock syndrome, where toxin-mediated injury drives morbidity. The binding site overlaps with that of macrolides and streptogramin B antibiotics, which accounts for the cross-resistance commonly observed among these drug classes.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~90%; Tmax ~45 min (oral), 1–3 h (IM); food does not affect absorption | Reliable IV-to-oral step-down; can be taken with or without meals |
| Distribution | Vd 0.6–1.2 L/kg; ~93% protein bound (primarily to alpha-1-acid glycoprotein); excellent bone, abscess, and tissue penetration; does NOT cross blood-brain barrier adequately | Suitable for osteomyelitis; not appropriate for meningitis; concentrations may vary in patients with altered alpha-1-acid glycoprotein levels |
| Metabolism | Hepatic via CYP3A4 and CYP3A5; major metabolites: clindamycin sulfoxide (active) and N-demethylclindamycin | Drug interactions with CYP3A4 inhibitors/inducers; rifampicin co-administration increases clindamycin clearance by ~43% |
| Elimination | t½ 2–3 h (young adults), ~4 h (elderly); ~10% excreted unchanged in urine; remainder via hepatic metabolism and biliary excretion; not removed by hemodialysis or peritoneal dialysis | No renal dose adjustment needed; slight half-life prolongation in severe hepatic disease; dosing q8h avoids accumulation |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea (non-C. difficile) | 10–30% | Dose-dependent; higher rates at 600 mg oral doses versus 300 mg; usually self-limiting upon discontinuation |
| GI discomfort (nausea, abdominal pain, cramping) | ~20% | Most common at higher oral doses; taking with food may help but does not alter absorption |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Morbilliform skin rash | ~10% | Most frequently reported non-GI reaction; particularly common in HIV/AIDS patients; usually mild-moderate and generalized |
| Pseudomembranous colitis (C. difficile) | ~6% | Can present up to 2 months after therapy ends; discontinue clindamycin immediately if suspected |
| Vomiting | 1–5% | More common with oral dosing |
| Metallic or unpleasant taste | 1–3% | Reported primarily with high-dose IV administration |
| Injection site reactions (pain, induration, thrombophlebitis) | 2–6% | Minimize by giving deep IM injections and avoiding prolonged indwelling IV catheters |
| Vaginal candidiasis (with vaginal formulation) | ~6% | Yeast overgrowth secondary to disruption of vaginal flora |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Clostridioides difficile colitis (fulminant/toxic megacolon) | ~2.5% | During therapy or up to 2 months post-treatment | Stop clindamycin immediately; obtain stool C. difficile toxin assay; initiate oral vancomycin or fidaxomicin; IV metronidazole for severe cases; surgical consult if toxic megacolon |
| Anaphylaxis / severe hypersensitivity | Rare | Minutes to hours after dose | Stop drug; epinephrine, airway management, supportive care; permanent discontinuation |
| Stevens-Johnson syndrome / Toxic epidermal necrolysis | Very rare | 1–4 weeks | Immediate discontinuation; dermatology and burn-unit consultation; supportive care |
| DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) | Very rare | 2–8 weeks | Discontinue clindamycin; systemic corticosteroids may be needed; monitor for organ involvement |
| Acute generalized exanthematous pustulosis (AGEP) | Very rare | Days after initiation | Discontinue drug; usually self-resolves; supportive care |
| Agranulocytosis / Thrombocytopenia | Rare (case reports) | Variable | Obtain CBC; discontinue clindamycin; haematology consultation |
| Acute kidney injury | Rare | Variable | Monitor renal function; discontinue if acute renal failure develops; supportive care |
| Cardiopulmonary arrest / Hypotension | Rare | During or immediately after rapid IV infusion | Avoid rapid IV push; adhere to max 30 mg/min infusion rate; resuscitative measures if needed |
| Hepatotoxicity (jaundice, elevated LFTs) | Rare | Variable | Periodic LFTs in prolonged therapy; discontinue if significant elevation |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Diarrhea / GI intolerance | ~10–15% | Most common cause; dose-related; higher rates with 600 mg oral dosing |
| C. difficile colitis | 2–6% | Mandatory discontinuation; requires specific anti-C. difficile therapy |
| Skin rash / Hypersensitivity | ~3% | Particularly common in HIV/AIDS population |
Diarrhea is the dominant clinical concern with clindamycin. Mild diarrhea without systemic symptoms may be managed supportively with rehydration while continuing therapy under close observation. However, do NOT use antiperistaltic agents (loperamide, diphenoxylate/atropine), as these can worsen or mask C. difficile colitis. Any patient developing watery diarrhea, bloody stools, abdominal cramps, or fever should have clindamycin stopped immediately and a stool C. difficile toxin assay obtained.
Drug Interactions
Clindamycin is metabolized hepatically via CYP3A4 and CYP3A5. It has clinically meaningful interactions with drugs that affect the same ribosomal binding site, neuromuscular blocking agents, and CYP3A modulators. The interaction with erythromycin is pharmacodynamic (overlapping binding sites), not metabolic.
Monitoring
-
Bowel Habits
Every visit / daily in inpatients
Routine Assess stool frequency and consistency at every contact. Any new-onset watery or bloody diarrhea, abdominal cramps, or fever warrants immediate stool testing for C. difficile toxin and consideration of drug discontinuation. Monitor for up to 2 months after treatment completion. -
Liver Function Tests
Baseline; periodically if prolonged therapy
Routine Obtain baseline AST, ALT, and bilirubin. Perform periodic LFTs when treating patients with severe hepatic disease or during therapy lasting longer than 10–14 days. Discontinue if significant elevations or jaundice develop. -
Renal Function
Baseline; if risk factors present
Trigger-based Acute kidney injury has been reported infrequently. Monitor creatinine in patients with pre-existing renal impairment or those receiving concomitant nephrotoxic drugs. -
Complete Blood Count
Baseline; if prolonged therapy or signs of infection
Trigger-based Transient neutropenia, eosinophilia, agranulocytosis, and thrombocytopenia have been reported. Obtain CBC if unexplained fever, mucosal ulceration, or bleeding occurs during therapy. -
Skin Assessment
Throughout therapy
Routine Watch for rash development. Discontinue immediately if blistering, mucosal involvement, or systemic symptoms suggestive of SJS/TEN or DRESS occur. -
Clinical Response
48–72 h after initiation
Routine Assess fever trend, wound appearance, and inflammatory markers. If no improvement by 48–72 hours, re-evaluate susceptibility data, source control, and appropriateness of empiric coverage.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to clindamycin, lincomycin, or any formulation component
- History of Clostridioides difficile colitis caused by prior lincosamide use
Relative Contraindications (Specialist Input Recommended)
- Previous C. difficile infection from any antibiotic — significant re-infection risk; document risk-benefit discussion; consider alternative agents
- Severe hepatic impairment — prolonged half-life reported; reduce dose and monitor LFTs closely; gastroenterology or hepatology input advisable
- Atopic individuals — the FDA PI advises avoidance in atopic patients due to heightened hypersensitivity risk
- Concurrent neuromuscular blocking agent use — risk of enhanced blockade and respiratory depression; anaesthesia team awareness essential
Use with Caution
- Elderly patients (>60 years) — higher incidence and greater severity of antibiotic-associated diarrhea and C. difficile colitis
- Patients receiving concurrent antibiotics — additional disruption of gut flora may compound C. difficile risk
- First trimester of pregnancy — no adequate controlled studies; use only if clearly needed
- Patients with aspirin hypersensitivity — the 75 mg and 150 mg oral capsules contain tartrazine (FD&C Yellow No. 5), which can cause allergic-type reactions including bronchial asthma
- Meningitis — clindamycin does not achieve adequate cerebrospinal fluid concentrations; not appropriate for CNS infections except toxoplasmic encephalitis (off-label, with pyrimethamine)
Clindamycin therapy has been associated with severe colitis that may prove fatal. CDAD has been reported with use of nearly all antibacterial agents, but clindamycin carries one of the highest risks. Treatment alters colonic flora, leading to overgrowth of C. difficile and production of toxins A and B. Hypertoxin-producing strains increase morbidity and mortality and may be refractory to antimicrobial therapy, sometimes requiring colectomy.
Because of this risk, clindamycin should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than two months after antibiotic therapy has ended.
Patient Counselling
Purpose of Therapy
Clindamycin is an antibiotic used to treat serious bacterial infections. It works by stopping bacteria from making the proteins they need to grow and multiply. It does not treat viral infections such as the common cold or influenza. Completing the full prescribed course is important to ensure the infection is fully treated and to reduce the risk of antibiotic resistance.
How to Take
Swallow capsules whole with a full glass of water (at least 180–240 mL) to prevent irritation of the throat and oesophagus. Do not lie down for at least 30 minutes after taking a capsule. Clindamycin may be taken with or without food. Take doses at evenly spaced intervals throughout the day. If using the oral solution, measure accurately with the provided device. Store the oral solution at room temperature and do not refrigerate, as it may thicken.
Sources
- Cleocin HCl (clindamycin hydrochloride) capsules, USP — Full Prescribing Information. Pfizer Inc. Pfizer PI Primary source for oral clindamycin dosing, pharmacokinetics, adverse reactions, and boxed warning language.
- Clindamycin Phosphate in 0.9% Sodium Chloride Injection — Full Prescribing Information. Baxter/FDA. FDA Label (2022) Primary source for IV/IM dosing, infusion rate guidance, CYP3A4/3A5 interaction updates, and renal/hepatic considerations.
- Dalacin C (clindamycin) Capsules and Injection — Product Information. Pfizer. Pfizer International PI International product information providing additional detail on PID dosing, malaria combination therapy, and toxoplasmosis protocols.
- Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med. 1974;81(4):429–433. doi:10.7326/0003-4819-81-4-429 Landmark study establishing the association between clindamycin use and antibiotic-associated colitis; source for colitis incidence of ~2.5%.
- Gurwith MJ, Rabin HR, Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. J Infect Dis. 1977;135(Suppl):S104–S110. doi:10.1093/infdis/135.Supplement.S104 Source for overall GI side effect incidence (21.5%) and diarrhea rates (13.5%) in a 200-patient cohort.
- Nathwani D, et al. Impact of Clindamycin on the Oral-Gut Axis: Gastrointestinal Side Effects and Clostridium difficile Infection. PMC. 2024. PMC11710861 Recent dose-response study (45 patients) demonstrating significantly higher GI side effect rates with 600 mg versus 300 mg oral doses.
- Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the IDSA for the treatment of MRSA infections in adults and children. Clin Infect Dis. 2011;52(3):e18–e55. doi:10.1093/cid/ciq146 IDSA guideline recommending clindamycin as an option for CA-MRSA skin and soft tissue infections; source for off-label dosing guidance.
- Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the AHA. Circulation. 2021;143(20):e963–e978. doi:10.1161/CIR.0000000000000969 AHA guideline specifying clindamycin 600 mg as a dental prophylaxis option for penicillin-allergic high-risk patients.
- McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by IDSA and SHEA. Clin Infect Dis. 2018;66(7):e1–e48. doi:10.1093/cid/cix1085 IDSA/SHEA guideline identifying clindamycin as a high-risk antibiotic for C. difficile infection; source for CDAD management recommendations.
- Schlunzen F, Zarivach R, Harms J, et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001;413(6858):814–821. doi:10.1038/35101544 X-ray crystallography study defining the 50S ribosomal binding site for lincosamides, macrolides, and streptogramins; basis for understanding cross-resistance.
- Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158(1):23–28. doi:10.1093/infdis/158.1.23 Key experimental study demonstrating clindamycin’s superiority over penicillin for high-inoculum streptococcal infections and its toxin-suppressive effect.
- Gatti G, Flaherty J, Bubp J, et al. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother. 1993;37(5):1137–1143. doi:10.1128/AAC.37.5.1137 Source for definitive PK parameters in healthy adults (CL 0.27 L/h/kg, Vd 0.79 L/kg, t½ 2.1 h, oral F 53% in crossover study).
- Serafin A, et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br J Clin Pharmacol. 2012;74(6):971–977. doi:10.1111/j.1365-2125.2012.04292.x Population PK study in osteomyelitis patients establishing the 43% increase in clindamycin clearance with rifampicin co-administration and the weight-based dosing recommendation of 900 mg TID for patients above 75 kg.
- Murphy PB, Bistas KG, Le JK. Clindamycin. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024 (updated February 28, 2024). NCBI Bookshelf Comprehensive review article covering clindamycin indications, pharmacology, adverse effects, and antimicrobial stewardship considerations.